Discover how digital innovation in the pharmaceutical sector is revolutionizing drug development, accelerating treatments, and transforming healthcare.

Poolbeg Pharma secures key patent extension for POLB 001 in South Korea until December 2038, reinforcing its global IP strategy and commercial value.

Discover how Poolbeg Pharma is revolutionizing the delivery of GLP-1R agonists to combat metabolic diseases like diabetes and obesity on a global scale.

Poolbeg Pharma is gearing up for BioTrinity 2025. Don’t miss this premier life sciences event!

Discover how artificial intelligence is revolutionizing the drug development process, reducing costs, accelerating timelines, and improving patient recruitment.

Discover how AI is revolutionising drug development and protein engineering in life sciences, shaping the future of healthcare and biotechnology.

Experience the transformative era in cancer treatment strategies! Learn about groundbreaking therapies, innovative drug designs, and major advancements in oncology by 2025.

HOOKIPA Pharma is advancing HIV treatment with its Phase 1b trial for HB-500. This innovative therapy aims to boost immune responses in individuals with HIV.

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

HOOKIPA Pharma Inc. and Poolbeg Pharma plc are in discussions for a potential acquisition to create a leading biopharmaceutical company focused on innovative medicines.